Sagimet Biosciences Inc. Series A Common Stock (SGMT) is a publicly traded Healthcare sector company. As of September 9, 2026, SGMT trades at $11.09 with a market cap of $680.02M and a P/E ratio of -6.84. SGMT moved +3.50% today. Year to date, SGMT is +80.91%; over the trailing twelve months it is +52.35%. Its 52-week range spans $1.73 to $11.41. Analyst consensus is strong buy with an average price target of $33.67. Rallies surfaces SGMT's financials, insider trades, hedge fund holdings, congressional trades, analyst ratings, and AI-generated research below.
Rallies tracks hedge fund and 13F ownership for SGMT, including fund holders, share counts, and position changes when data is available.
| Metric | Value |
|---|---|
| Price | $11.09 |
| Market Cap | $680.02M |
| P/E Ratio | -6.84 |
| EPS | $-1.58 |
| Dividend Yield | 0.00% |
| 52-Week High | $11.41 |
| 52-Week Low | $1.73 |
| Volume | 8.76K |
| Avg Volume | 0 |
| Revenue (TTM) | $0 |
| Net Income | $-51.04M |
| Gross Margin | 0.00% |
6 analysts cover SGMT: 0 strong buy, 6 buy, 0 hold, 0 sell, 0 strong sell. Consensus rating is strong buy. Average price target: $33.67.